Page 3 - Sanofi

US to pay Sanofi, GSK $2.1 bn for Covid-19 vaccine to cover 50 mn people

A Sanofi executive said the companies had not yet agreed with the US on a specific price for additional doses

US pledges up to $2.1 billion for Sanofi, GlaxoSmithKline Covid-19 vaccine

Glaxo shares traded 1.6 per cent higher in London, with Sanofi up 1.4 per cent in Paris

Sanofi lifts earnings view as Regeneron stake sale boosts second quarter

Sanofi is working on two of the more than 150 potential Covid-19 vaccines being developed across the world

World Coronavirus Dispatch: WHO stops trials of HCQ, HIV cocktail

Glaxo, Sanofi near $624 mn vaccine deal, Mexico deaths top 30,000, uneven recovery for Arab world and other pandemic-related news across the globe

Families struggle to import life-saving drugs as lockdown hits grey market

With no new stock coming in, both patients and grey market vendors started running out of vigabatrin

Second-generation Covid-19 vaccines are built for impact over speed

Some of the world's most prolific and experienced vaccine developers -- Sanofi, GlaxoSmithKline and Merck & Co - are among at least 100 challengers trailing the leaders

Sanofi eyes Covid-19 vaccine approval in early 2021; partners Translate Bio

Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale

Sanofi stops enrolling Covid-19 patients in hydroxychloroquine trials

The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug

Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares

Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership

GlaxoSmithKline, Sanofi strike deal to develop coronavirus vaccine

The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year.

Biocon, Mylan win patent case for insulin device against Sanofi in US

Development takes Biocon a step closer to commercialise its glargine biosimilar Semglee in America

Sanofi to sell surgical product unit Seprafilm to Baxter for $350 mn

The deal should close by the end of the first quarter of 2010, Baxter added in a statement confirming the purchase, which was reported earlier by Reuters

Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker

Novartis shares were seen up 0.2%, premarket indicators showed.

Unlocking trapped value: Sanofi mulls $30 bn consumer business spinoff

All businesses are undergoing thorough reviews at the moment, according to the Paris-based company.

Sanofi to reward shareholders with Rs 261 cr made from Ankleshwar unit sale

The sale will translate into average annual revenue loss of Rs 470 cr, which Sanofi plans to mitigate through renewed focus on core activities and brands

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

Shares of Lexicon fell nearly 40% in extended trading

Sanofi partners Google to use AI, analytics tools for better treatments

The use of Google's tools for deep analytics -- organising large amounts of data to make insights -- will help it better understand key diseases and patient outcomes to make further improvements

Sanofi: Strong anti-diabetic range, exports may prove healthy for investors

Despite the cut in forward estimates due to pressure on margins, earnings are expected to grow by more than 20 per cent annually over the next two years

Bitter pill to swallow: Margin worries ahead for Sanofi

Price cuts, a higher share of exports have led to a revision of margin estimates